🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

Recruitingn/aAges 18 Years - anyAllBlueprint Medicines Corporation
NCT07255638 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants is starting avapritinib treatment at the HCP's discretion as part of their routine care (for ISM with moderate to severe symptoms inadequately controlled with symptomatic treatment) and in accordance with approved SmPC. Exclusion Criteria: * Participant with a potential increased risk for intracranial hemorrhage including those with a history of vascular aneurysm, intracranial hemorrhage, cerebrovascular accident within the prior year, or severe thrombocytopenia. * Participant who has previously taken avapritinib as a commercial drug or as part of a clinical study.
💊

What it tests

  • Avapritinib
📍

Where

12 sites
Charité Universitätmedizin Berlin, Institut für Allergieforschung
Berlin, Germany
Katholisches Klinikum Bochum
Bochum, Germany
MVZ Klinikum Deggendorf
Deggendorf, Germany
Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie
Dresden, Germany
Universitatsmedizin Freiburg, Klinik fur Innere Medizin
Freiburg im Breisgau, Germany
University Medical Center Goettingen - Georg August University of Goettingen
Göttingen, Germany
Klinik fur Hamatologie Universistatklinik Leipzig
Leipzig, Germany
Technische Universitat Munchen, Studienzentrum der Klinik fur Dermatologie am Biedertein
Munich, Germany

…and 4 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy